Erik van den Berg

Erik has over 20 years of experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several biotech companies. Previously, as a senior executive at Organon (now Merck) he was responsible for leading the company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600 million option to acquire AM-Pharma by Pfizer and raised more than €130 million in equity and debt financing. Erik has an MSc in chemistry from the University of Utrecht and an MBA from Manchester Business School, both with honors.

Back to about us